Italian group posts strong Q3 results, reaffirming 2026 targets. It is planning the GN Hearing integration in detail but will keep its commercial dealings with GN unchanged until the deal closes.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a corporate financial and M&A update with no direct implications for clinical practice.
If regulators approve Amplifon's acquisition of GN Hearing, the combined entity would reshape the competitive landscape for hearing-aid supply and dispensing globally, with potential downstream effects on product availability and pricing for clinics.
- 01Amplifon reported strong Q3 financial results and reaffirmed its 2026 strategic targets.
- 02Integration planning for the GN Hearing acquisition is underway but commercial dealings with GN remain unchanged pending regulatory clearance.
- 03The deal is being handled carefully to avoid triggering competition authority concerns.
- 04The acquisition would combine one of the largest retail hearing-aid chains with a major manufacturer.
- 05No timeline for regulatory approval has been publicly confirmed.
Amplifon reported strong Q3 results.
press releasepartially supportedAmplifon reaffirmed its 2026 strategic and financial targets.
press releasepartially supportedCommercial dealings with GN Hearing remain unchanged pending regulatory clearance of the acquisition.
press releasesupported
